MYC (also known as c-MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. MYC is a transcription factor, and many of its protumorigenic functions have been attributed to its ability to regulate gene expression programs 1-3 . Notably, oncogenic MYC activation has also been shown to increase total RNA and protein production in many tissue and disease contexts 4-7 . While such increases in RNA and protein production may endow cancer cells with pro-tumour hallmarks, this increase in synthesis may also generate new or heightened burden on MYC-driven cancer cells to process these macromolecules properly 8 . Here we discover that the spliceosome is a new target of oncogenic stress in MYC-driven cancers. We identify BUD31 as a MYC-synthetic lethal gene in human mammary epithelial cells, and demonstrate that BUD31 is a component of the core spliceosome required for its assembly and catalytic activity. Core spliceosomal factors (such as SF3B1 and U2AF1) associated with BUD31 are also required to tolerate oncogenic MYC. Notably, MYC hyperactivation induces an increase in total precursor messenger RNA synthesis, suggesting an increased burden on the core spliceosome to process pre-mRNA. In contrast to normal cells, partial inhibition of the spliceosome in MYC-hyperactivated cells leads to global intron retention, widespread defects in pre-mRNA maturation, and deregulation of many essential cell processes. Notably, genetic or pharmacological inhibition of the spliceosome in vivo impairs survival, tumorigenicity and metastatic proclivity of MYC-dependent breast cancers. Collectively, these data suggest that oncogenic MYC confers a collateral stress on splicing, and that components of the spliceosome may be therapeutic entry points for aggressive MYC-driven cancers.
MYC (also known as c-MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. MYC is a transcription factor, and many of its protumorigenic functions have been attributed to its ability to regulate gene expression programs [1] [2] [3] . Notably, oncogenic MYC activation has also been shown to increase total RNA and protein production in many tissue and disease contexts [4] [5] [6] [7] . While such increases in RNA and protein production may endow cancer cells with pro-tumour hallmarks, this increase in synthesis may also generate new or heightened burden on MYC-driven cancer cells to process these macromolecules properly 8 . Here we discover that the spliceosome is a new target of oncogenic stress in MYC-driven cancers. We identify BUD31 as a MYC-synthetic lethal gene in human mammary epithelial cells, and demonstrate that BUD31 is a component of the core spliceosome required for its assembly and catalytic activity. Core spliceosomal factors (such as SF3B1 and U2AF1) associated with BUD31 are also required to tolerate oncogenic MYC. Notably, MYC hyperactivation induces an increase in total precursor messenger RNA synthesis, suggesting an increased burden on the core spliceosome to process pre-mRNA. In contrast to normal cells, partial inhibition of the spliceosome in MYC-hyperactivated cells leads to global intron retention, widespread defects in pre-mRNA maturation, and deregulation of many essential cell processes. Notably, genetic or pharmacological inhibition of the spliceosome in vivo impairs survival, tumorigenicity and metastatic proclivity of MYC-dependent breast cancers. Collectively, these data suggest that oncogenic MYC confers a collateral stress on splicing, and that components of the spliceosome may be therapeutic entry points for aggressive MYC-driven cancers.
To discover genes and cellular processes required to tolerate oncogenic MYC expression, we previously performed a genome-wide MYC-synthetic lethal screen in human mammary epithelial cells (HMECs) engineered with an inducible MYC and oestrogen receptor fusion protein (MYC-ER) for candidates affecting cell viability in a MYC-selective manner 9 . This screen nominated BUD31 as a candidate MYC-synthetic lethal gene ( Fig. 1a ), in which barcoded BUD31 short hairpin RNAs (shRNAs) consistently dropped out of the population in MYC-hyperactivated cells relative to cells without MYC induction (Fig. 1b) . In validation experiments, BUD31 depletion restrained clonogenic growth and activated apoptosis in MYC-induced cells, as compared to MYC-normal cells (Extended Data Fig. 1a-c) . Expression of shRNA-resistant BUD31 rescued the MYC-synthetic lethal phenotype of BUD31 shRNA ( Fig. 1c and Extended Data Fig. 1d ), indicating that the phenotype is an RNA interference (RNAi) on-target effect.
BUD31 has been linked to the spliceosome in yeast 10 , but its function in mammalian systems has not been determined. To uncover the molecular function(s) of BUD31, we identified BUD31-interacting proteins by Flag-tagged BUD31 immunoprecipitation from cells with or without RNase A (which eliminates protein-protein interactions mediated by RNA tethering), followed by mass spectrometry. Remarkably, 79 out of 134 core spliceosomal components were associated with BUD31 (Extended Data Fig. 2a ), suggesting a strong association between BUD31 and the spliceosome in human cells.
The spliceosome is a dynamic molecular machine consisting of several nuclear protein complexes that cycle on and off of pre-mRNA during intronic splicing 11 . Co-immunoprecipitation experiments confirmed that BUD31 associates with several subcomplexes of the spliceosome, including the Prp19-CDC5L subcomplex (PRPF19), the U2 small nuclear ribonucleoprotein particles (snRNPs; SF3B1 and SF3A1), U2-related factors (U2AF1), the U5 snRNP (EFTUD2), and Sm proteins (SNRPF) ( Fig. 1d and Extended Data Fig. 2c ), but interaction with non-spliceosomal proteins was not detected (Extended Data Fig. 2d, e ). To test more broadly the association of BUD31 with subcomplexes of the spliceosome, we performed bimolecular fluorescence complementation (BiFC) between BUD31 and proteins from each major spliceosomal subcomplex. BiFC analysis indicated that BUD31 associates with components of the major snRNPs (U1, U2, U4/U6 and U5) as well as Sm proteins ( Fig. 1e and Extended Data Fig. 2b ), indicating that BUD31 is present at several stages of spliceosomal assembly.
To examine more directly whether BUD31 has a role in pre-mRNA splicing, we tested in vitro splicing efficiency using nuclear extracts with or without BUD31 knockdown. BUD31 loss significantly inhibited pre-mRNA splicing (Extended Data Fig. 2f-i ). In addition, knockdown of BUD31 led to defects in early spliceosome assembly, as indicated by impaired formation of complex A (Extended Data Fig.  2h , i). Collectively, these data indicate that HMECs require a core spliceosomal protein (BUD31) to tolerate dysregulated MYC.
We proposed that cells with oncogenic MYC required BUD31 for cell survival because of its role in the spliceosome. To test this hypothesis, we generated a BUD31 mutant deficient in binding core spliceosomal proteins by mutating a highly conserved region spanning a C 2 -C 2 zinc-finger. Mutation of this region abrogated BUD31 interaction with spliceosomal proteins (Extended Data Fig. 2j ). To determine whether this region is also necessary for cells to tolerate MYC hyperactivation, we performed an in vitro competition assay. Green fluorescent protein (GFP)-expressing MYC-driven breast cancer cells encoding inducible BUD31 shRNA were transduced with shRNA-resistant wild-type or mutant BUD31 complementary DNA, and these cells were mixed with non-transduced, GFP-negative cells. BUD31 knockdown significantly inhibited the proliferation of MYCdriven cancer cells. Proliferation was fully rescued by wild-type BUD31 cDNA but not by a BUD31 mutant deficient in spliceosomal binding ( Fig. 1f ), suggesting that BUD31 association with the spliceosome is required to support the survival of MYC-hyperactivated cells. More broadly, these results indicate that oncogenic MYC may increase cellular dependency on spliceosome function. By contrast, ectopic expression of the oncogenes HER2 (also known as ERBB2) and EGFR did not enhance the effects of BUD31 depletion (Extended Data Fig. 3a, b ), suggesting that the stress imposed by MYC on spliceosomal function is not a universal feature of the oncogenic state.
To test whether one or more subcomplexes of the spliceosome are required to tolerate aberrant MYC activity, we examined additional components of spliceosome assembly and catalysis including SF3B1 (U2 snRNP), U2AF1 (U2-related splicing factor), EFTUD2 (U5 snRNP) and SNRPF (core Sm protein found in every snRNP complex). Notably, partial depletion of each spliceosomal component led to loss of cell viability ( This suggests that several subcomplexes of the core spliceosome are required for cells to tolerate oncogenic MYC, and that MYC-hyperactivated cells are sensitive to modest perturbations in spliceosome function.
Next, we investigated whether pharmacological inhibition of the spliceosome is also synthetic lethal with MYC. Several pharmacological agents (for example, FR901464, pladienolides and their derivatives) have been characterized to bind the core SF3b spliceosomal complex components and inhibit spliceosome function 12 . However, most of these inhibitors are not amenable for in vivo delivery. We developed a new small molecule inhibitor of SF3B1, known as SD6, that impairs spliceosome function and is bioavailable in mammals 13 . Consistent with our genetic data, low SD6 concentrations significantly suppressed colony formation ( Fig. 1g ) and induced apoptosis (Extended Data Fig. 4i ) in a MYC-selective manner. The synthetic-lethal interaction between MYC hyperactivation and core spliceosome perturbation suggests that pre-mRNA splicing is necessary to tolerate oncogenic MYC.
In many different cell lineages and experimental systems, oncogenic MYC activation has been shown to amplify the synthesis of cellular mRNA through direct or indirect mechanisms 4, 5, 14, 15 . In agreement, MYC hyperactivation in HMECs increased total cellular mRNA synthesis and mRNA steady-state levels ( Fig. 2a ) without an increase in cellular growth rate (Extended Data Fig. 3c ). In contrast to a recent report in B-cell compartments 16 , MYC hyperactivation did not affect the levels of spliceosome proteins in HMECs (data not shown), suggesting that increased pre-mRNA dosage is not compensated for by higher spliceosome levels. Thus, we proposed that the MYC-induced increase in global mRNA synthesis confers increased pressure on the spliceosome to process pre-mRNAs, and partial perturbation of the spliceosome would lead to widespread defects in the splicing of pre-mRNA introns in the MYChyperactive state. To test this hypothesis, we compared intron retention (IR) after BUD31 knockdown in MYC-normal or MYC-hyperactivated cells. We performed RNA-sequencing (RNA-seq) from cells in each state (normal, BUD31 knockdown, MYC-hyperactive, and MYC-hyperactive with BUD31 knockdown) and determined the pre-mRNA splicing efficiency by calculating IR at junctions across the genome (Fig. 2b) . Because the analysis of intronic reads may be influenced by the presence of stable RNAs within introns and/or spliced lariats, we restricted the analysis to reads directly spanning exon-intron or exon-exon junction sequences (75,623 junctions in 6,861 genes) (see Methods). 
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To examine the effects of spliceosome perturbation in the normal and oncogenic MYC states, we compared the effect of BUD31 knockdown on junction IR coefficients in wild-type and MYC-hyperactivated cells. Notably, BUD31 depletion caused significantly more IR in the MYC-hyperactive state than in the MYC-normal state ( Fig. 2c , P , 10 2324 ). Similar results were observed when junction coefficients were computed on a gene level ( Fig. 2d , P , 10 2189 ). The increase in IR conferred by aberrant MYC activation and BUD31 shRNA was validated on individual exon-intron junctions via quantitative reverse transcriptase PCR (qRT-PCR) (examples in Fig. 2e -j). IR was not limited to a few discrete genes. Instead, BUD31 knockdown in the MYC-hyperactive state led to significantly increased IR in 42% of genes analysed (2,848 of 6,861, P , 0.05). These data indicate that the combination of oncogenic MYC activation and partial spliceosome inhibition leads to a widespread increase in IR. This is consistent with the hypothesis that the MYC-induced increase in pre-mRNA synthesis enhances cellular dependency on optimal spliceosome function by raising the level of pre-mRNA substrates for spliceosomal processing.
Intron-retaining pre-mRNAs often fail to complete mRNA maturation and are commonly degraded via quality control mechanisms 17 . Because the combination of MYC hyperactivation and spliceosome inhibition led to a global increase in intron retention ( Fig. 2c, d ), we proposed that these cells may contain widespread defects in pre-mRNA maturation and stability ( Fig. 3a) . To test this hypothesis, we measured the levels of cellular poly(A) 1 RNA in each of the four states (with/ without MYC hyperactivation, with/without BUD31 shRNA) before and after treatment with the transcriptional inhibitor actinomycin D. After actinomycin D treatment, cellular poly(A) 1 RNA decreased by comparable levels (,16-19%) in control cells with or without BUD31 knockdown ( Fig. 3b ). Notably, MYC-hyperactivated cells exhibited enhanced mRNA stability, perhaps resulting from increased polysomal loading of mRNA during MYC-induced translation 18 . By contrast, cells containing MYC hyperactivation and BUD31-depletion exhibited a substantially greater loss (38%) of poly(A) 1 RNA after actinomycin D treatment, suggesting a defect in pre-mRNA maturation and/or stability in the combined MYC-hyperactivated and BUD31-shRNA state. Similarly, fluorescence in situ hybridization (FISH) measurements Relative 
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of poly(A) 1 RNA revealed that the combination of MYC hyperactivation and BUD31 knockdown led to a substantially greater decrease (60%) in poly(A) 1 RNA after actinomycin D treatment (Extended Data Fig. 5a ). Similar trends were observed in nuclear RNA pools, consistent with defects in nuclear pre-mRNA maturation (Extended Data Fig. 5b ). Consistent with this decrease in pre-mRNA maturation and stability, cells containing oncogenic MYC and BUD31 knockdown exhibited significantly lower (54%) steady-state levels of poly(A) 1 RNA (Fig. 3c ). Collectively, these results indicate that MYC hyperactivation increases cellular pre-mRNA synthesis, and inhibition of the spliceosome reduces the cellular capacity to process this pre-mRNA burden. The result of this MYC-hyperactivated and spliceosome-hypomorphic state is enhanced intron retention, decreased mRNA maturation and stability, and a significant loss of steady-state cellular mRNA.
Gene Ontology analysis of genes with the most significant intron retention in the combined MYC-hyperactive and BUD31-depleted state (2,848 out of 6,816 genes analysed for IR) suggests that many essential processes and subcellular structures were affected, including gene expression, DNA replication and repair, the mitotic spindle, unfolded protein response, and RNA splicing ( Fig. 3d ). Many genes participating in these essential cell processes exhibited increased IR in the combined MYC-hyperactive and BUD31-knockdown state (representative genes in Fig. 3e ) and a concomitant decrease in RNA levels, consistent with a defect in maturation and stability of IR-containing transcripts ( Fig. 3f ). Consistent with their role in crucial cellular processes, knockdown of these genes reduced cell number by 0.7-4.2-fold (as quantified by barcode-tag abundance, Extended Data Fig. 6 ). Together, these data are consistent with the hypothesis that the combination of oncogenic MYC and spliceosome inhibition leads to widespread loss of mRNA integrity, resulting in the deregulation of many essential genes and processes instead of a single pathway.
Because oncogenic MYC significantly increases the sensitivity of HMECs to inhibition of the spliceosome, we proposed that MYC-driven cancers may be hyperdependent on core spliceosomal function to support their survival. We queried whether MYC-driven breast cancer cell lines exhibit increased sensitivity to knockdown of core spliceosomal genes. Recently, we conducted genome-wide RNAi screens in a panel of 72 breast cancer and immortalized cell lines for genes affecting cell viability ( Fig. 4a ) (R.M., A.S. and B.G.N., manuscript in prepara-tion). From this data set, we tested for a correlation between MYC-dependency (as indicated by sensitivity to MYC shRNAs) and dependency on the spliceosome (as indicated by sensitivity to shRNAs targeting spliceosome components in the shRNA library), or on 100,000 randomly drawn gene sets. Notably, MYC-dependent breast cancer cell lines were significantly more sensitive to shRNAs targeting the core spliceosome ( Fig. 4b , P 5 0.005). The correlation between MYCdependency and spliceosome-dependency was significantly pronounced in the basal breast cancer lines ( Fig. 4c , P , 0.00001), an aggressive molecular subtype of breast cancer frequently driven by MYC.
Triple-negative breast cancers are commonly driven by MYC, and exhibit an aggressive, highly metastatic clinical course. To determine whether MYC-driven triple-negative breast cancers are dependent on spliceosomal integrity for their tumorigenic and metastatic proclivity, we tested the effects of genetic and pharmacological inhibition of the spliceosome on MYC-dependent and metastatic triple-negative breast cancer (TNBC) models. Inducible BUD31 shRNA reduced cell viability and increased apoptosis in MYC-dependent TNBC cells in vitro (Fig. 4d , e and Extended Data Fig. 7a, b ). Similar to MYC-ER HMECs, MYC protein levels remained unchanged during BUD31 depletion in these MYC-dependent cancer cell lines (Extended Data Fig. 8a, b ), suggesting that the apoptotic response was not due to loss of the driver oncogene (MYC). To assess the effect of spliceosomal perturbation on tumour growth, we established a pooled competition assay that uses shRNA-associated barcodes to detect changes in tumour cell fitness (Extended Data Fig. 9 ). In the metastatic TNBC cell line MDA-MB-231-LM2 (LM2) 19 , inducible MYC-shRNA-expressing cells dropped out of the tumour population, confirming the MYC dependency of this TNBC model ( Fig. 4f) . Similarly, tumour cells containing BUD31 or SF3B1 shRNA dropped out of the tumour population ( Fig. 4f ). Tumorigenicity of another MYC-dependent TNBC model (SUM159) was similarly impaired by BUD31 depletion (Extended Data Fig. 7c, d) . These data suggest that the loss of BUD31 or other core spliceosomal factors inhibits MYC-dependent breast cancer growth in vivo.
Because MYC-driven breast cancers are prone to metastasize to visceral organs including the lungs 20 , we tested whether perturbation of spliceosome function affected metastatic expansion of MYCdependent LM2 cells. As shown in Fig. 4g , metastatic cells with BUD31 knockdown were significantly depleted from the population 
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(.133.5-fold change), with most doxycycline (dox)-positive tumours containing BUD31 shRNA barcodes below the level of detection. These data suggest that BUD31 and the spliceosome are essential for MYCdependent breast tumorigenicity and metastatic expansion in vivo.
Next, we tested whether pharmacological inhibition of the spliceosome also impaired tumorigenic and metastatic potential of MYCdependent TNBC cells. Compared to MYC-normal cell lines (halfmaximal inhibitory concentration (IC 50 ) value < 53 nM), MYC-driven cancer cells were significantly more sensitive (IC 50 value < 4 nM) to the spliceosome inhibitor SD6 in vitro (Extended Data Fig. 10a ). Similarly, SD6 suppressed the proliferation of a MYC-driven B-cell model 4 (Extended Data Fig. 10b ), suggesting that oncogenic MYC may confer hyperdependency on the spliceosome in many epigenetic backgrounds and cancer types. In primary LM2 tumour xenografts, SD6 potently restrained tumour growth with no toxicities in any organ system examined, suggesting that splicing is essential for the tumorigenicity of these MYC-dependent breast cancer cells (Fig. 4h) . Similarly, SD6 impaired lung metastatic expansion in experimental metastasis assays (Fig. 4i) , and extended progression-free survival (Extended Data Fig. 10c ). Collectively, these data suggest that MYC-driven breast cancers depend on spliceosomal integrity for their tumorigenic and metastatic progression.
Altogether, the results suggest that MYC-driven breast cancers contain an enhanced dependency on the core spliceosome. Recent studies have shown that MYC regulates splicing of select genes via induction of alternative splicing factors or components of the core spliceosome 16, 21 .
This study suggests that MYC may induce a much broader stress on splicing via its ability to increase global pre-mRNA synthesis. Recently, there has been considerable investigation into how MYC elicits a widespread increase in mRNA synthesis across the transcriptome 4, 5, 22, 23 . Notably, either direct or indirect mechanisms of increased pre-mRNA synthesis elicited by MYC could lead to an enhanced dependency on the spliceosome, and thus make MYC-driven cancers candidates for spliceosome-based therapies. These observations provoke the important question of whether MYC-induced amplification of mRNA synthesis may also generate vulnerabilities in other aspects of RNA processing (such as mRNA capping, polyadenylation or mRNA export) and downstream protein biosynthesis 24 in MYC-driven cancers. Notably, the spliceosome may be a target of both oncogene addiction and oncogenic stress. Components of the U2 snRNP, such as SF3B1 and U2AF1, contain frequent and recurrent somatic mutations that cluster in an evolutionarily conserved domain, suggestive of oncogenic function 25, 26 . On the basis of such putative oncogenic functions, the spliceosome has been proposed as a target for classical oncogene addiction, in which spliceosome mutant tumours may be addicted to the oncogenic functions of spliceosome mutants and thus sensitive to spliceosome inhibitors. However, this study and others 27, 28 have shown that inhibition of spliceosome components is deleterious in cancer cell line models that lack spliceosome mutations, suggesting that other drivers of cancer (such as MYC) are determinants of sensitivity to spliceosome inhibitors. Because oncogenic MYC is known to drive several pro-tumorigenic programs that include rewiring of biosynthetic pathways 29, 30 , our model provokes the important hypothesis that cellular processes (such as splicing) that enable cancer cells to tolerate such widespread shifts in macromolecular synthesis may provide entry points for anti-cancer therapies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Vectors and virus production. Commercially available pGIPZ shRNAs targeting BUD31 (V2LHS_47771 and V2LHS_47770), EFTUD2 (V2LHS_28167), SF3B1 (V3LHS_397872), SNRPF (V2LHS_276933) and U2AF1 (V2LHS_84677) were obtained from Open Biosystems. shRNAs targeting the 39 UTR region of BUD31 were designed using the BiopredSI and RNAi Codex algorithms (shRNA sequence 59-TGCTGTTGACAGTGAGCGCCGCTGTCTATCAGCTG TGATTTAGTGAAGCCACAGATGTAAATCACAGCTGATAGACAGCGATG CCTACTGCCTCGGA-39). For inducible RNAi experiments, shRNAs were subcloned into the pINDUCER dox-inducible lentiviral expression system 31 . Lentiviruses and retroviruses were produced by transiently transfecting shRNA or cDNA constructs using Mirus Bio TransIT transfection protocols into 293T cells and collecting viral supernatants 48 h after transfection. Cell culture. HMECs expressing hTERT and inducible MYC-ER (MYC-ER HMECs), F7 epithelial cells and human mammary epithelial HME1 cells were cultured in mammary epithelial growth medium (MEGM, Lonza). 293T cells, HeLa cells and MDA-MB-231-LM2 human breast cancer cells were cultured in DMEM (Gibco) supplemented with 10% FBS. SUM159 human breast cancer cells were cultured in F12 (Gibco) media supplemented with 5% FBS, 10 mM HEPES (Gibco), 5 mg ml 21 insulin (Invitrogen), and 1 mg ml 21 hydrocortisone. The P493-6 human B-cell lymphoma cell line was cultured in RPMI-1640 supplemented with 10% FBS (Clonotech) and 1% GlutaMAX (Invitrogen). All cell lines were incubated at 37 uC and 5% CO 2 . Cell lines were obtained from ATCC, and all cell lines are tested yearly for mycoplasma contamination. Stable cell lines expressing shRNAs or cDNAs were generated by lentiviral or retroviral transduction in the presence of 8 mg ml 21 polybrene followed by selection with appropriate antibiotic resistance markers. Cell proliferation assays. MYC-ER HMECs were infected with pINDUCER-shRNA viruses at a multiplicity of infection (MOI) of 1.3-1.5, and transduced cells were seeded at a density of 3,000 onto 96-well black plates (Corning). MYC-ER HMECs with pINDUCER-shBUD31-39UTR were treated with 300 nM 4-hydroxytamoxifen (4-OHT) to induce MYC hyperactivation, and with 32 ng ml 21 dox (Sigma) to induce shBUD31 expression. SUM159 and MDA-MB-231-LM2 (LM2) cells were infected with pINDUCER-shBUD31 virus (targeting the 39 UTR and coding region, respectively) at an MOI of 1.5, and seeded at a density of 1,000 and 2,000, respectively. Expression of shBUD31 in LM2 and SUM159 cells was induced with 1 mg ml 21 dox. HMECs and breast cancer cells were re-fed every 3-4 days until cells reached confluence. At confluence, cells were fixed in 4% paraformaldehyde, and nuclei were stained with Hoeschst3321 (1:1,000, Life Technologies). Nuclei were imaged and counted using the Celígo Imaging Cell Cytometer (Brooks).
For clonogenic assays, breast cancer or immortalized epithelial cells were seeded at low density (between 500 and 2,000 cells per plate, depending on the cell line) into 6-cm plates, four replicates per treatment group. MYC-ER HMECs with pINDUCER-shBUD31-39UTR were treated with 8 ng ml 21 dox and 300 nM 4-OHT, and MYC-ER HMECs treated with 10 or 20 nM SD6 were also cultured with 200 nM 4-OHT. Cells were re-fed every 4 days until colonies were macroscopic. The colonies were stained using Coomassie brilliant blue. Macroscopic colonies were quantified and normalized to vehicle-treated cells for each cell line.
For the P493-6 cell line with pmyc-tet construct 32 , MYC was reduced by treating cells with 0.1 mg ml 21 tetracycline (Sigma) for 72 h. MYC was induced by washing P493-6 cells with PBS twice, then culturing cells in RPMI-1640 medium with 10% Tet System Approved FBS (Clontech) and 1% GlutaMAX. P493-6 cells were treated with or without 100 nM SD6 and with or without 0.1 mg ml 21 tetracycline for 4 days. Immunoprecipitation and mass spectrometry. HeLa cells transduced with lentivirus encoding BUD31 cDNA and non-transduced HeLa cells were collected, and nuclear extracts as well as whole-cell lysates were collected as described previously 33 . Lysates were treated with RNase A (500 mg ml 21 ) for 1 h on ice. For immunoprecipitations, nuclear and whole-cell extracts were ultracentrifuged at 100,000g, and incubated with 25 mg M2 Flag antibody (Sigma) for 1 h, followed by ultracentrifugation and incubation with Sepharaose-CL4B Protein A beads (GE Healthcare). Beads were washed with NTN (50 mM Tris-Cl, pH 8.0, 150 mM NaCl and 0.5% NP-40), and immunocomplexes were resuspended in 13 Laemmli buffer and resolved on pre-cast 4-20% Novex Tris-Glycine gels (Life Technologies). Gels were minimally stained with Coomassie brilliant blue, cut into 8 molecular mass ranges, and digested with trypsin. Immunocomplexes were identified on a Thermo Fisher LTQ mass spectrometer, and data processing was performed as previously described 33 . Enrichment analysis. Human GO annotation file (gene_association.goa_human. gz) was downloaded from http://geneontology.org/GO.downloads.annotations. shtml containing a GOC Validation date of 2 September 2013. Enrichment analysis was performed to consider the content of (1) BUD31-associated proteins, or (2) genes with enhanced IR. Gene symbols annotated to BUD31-associated proteins were cross tabulated against all Gene Ontology annotations. Genes with enhanced IR were cross tabulated against the subset of Gene Ontology annotations for genes considered in this analysis. We used Fisher's exact test to determine P values for the proportion of genes overlapping each annotation set. BiFC. BUD31 was cloned into the pQCXIN-N-YFP fusion vector, in which the BUD31 N terminus was fused to the N-terminal domain (residues 1-155) of Venus yellow fluorescent protein (YFP). Human splicing factor cDNAs were individually recombined into retroviral vectors with C-terminal Venus YFP (residues 156-239) tags at the N-terminal ends. SUM159 breast cancer cells were transduced with these bait and prey BiFC retroviruses, and cellular fluorescence was analysed by flow cytometry in triplicate. BUD31 mutagenesis. Wild-type and mutant BUD31 cDNAs were generated by gene synthesis (IDT DNA) and recombined into the pQCXIN-N-YFP fusion vector. Mutant BUD31 consisted of substituting human BUD31 amino acid residues 105-114 with an equivalent number of glycine residues (codon GGA). In vitro competition assay. MYC-dependent SUM159 breast cancer cells with pINDUCER-shBUD31-39UTR were transduced with viruses containing wild-type or mutant BUD31 or negative control cDNA recombined into pQCXIN-N-YFP vectors. Infected, GFP 1 cells are mixed at an 80:20 ratio with non-transduced, GFP 2 parental cells and seeded into 96-well plates and treated either with or without dox (1 mg ml 21 ). At confluence, cells were passaged 1:10 and processed for flow cytometry. The in vitro competition assay was continued for two passages.
Immunoblotting. Cells were lysed in 13 SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 2.5% b-mercaptoethanol) and heated at 95 uC for 12 min. The following antibodies were used for western blotting: Flag (Sigma, A8592), BUD31 (ProteinTech, 11798-1-AP), SF3B1 (Bethyl, A300-996A), Prp19 (Bethyl, A300-101A), U2AF1 (Bethyl, A302-079A), SF3A1 (Bethyl, A301-603A), EFTUD2 (Bethyl, A300-957A), SNRPF (Abcam, 154870), HER2 (Millipore, 06-562), EGFR (Cell Signaling, 2232), cleaved caspase-3 (Cell Signaling, 9664), RPS8 (Assay Biotechnology, R12-3466), EIF2S1 (Abgent, AP13469 s), eIF3I (p36) (Biolegend, 646701) and c-Myc (D84C12) (Cell Signaling, 5605). Vinculin (Sigma, V9131) and Ran (BD Biosciences, 610340) were used as loading controls. In vitro transcription. Uniformly 32 P-UTP radiolabelled MINX pre-mRNA was in vitro transcribed from a BamHI-digested plasmid 34 , DNaseI (Ambion) treated and gel-isolated on a 8 M urea 6% polyacrylamide gel. In vitro splicing. HeLa nuclear extracts used for in vitro splicing assays were made as described previously 35 from HeLa cells transduced with an inducible BUD31targeting shRNA and grown in the presence or absence of 1 mg ml 21 dox. Splicing reactions of 15 ml contained: 8 nM RNA substrate, 0.8 mM DTT, 1.7 mM magnesium acetate, 1.7 mM ATP, 17 mM phospho-creatine, 20 mM glycine, 1 U ml 21 RNasin Plus (Promega), 3.7% PVA and 50 mg of HeLa nuclear extracts. Splicing reactions were incubated for indicated time points at 30 uC and stopped by digestion with proteinase K (Ambion) for 30 min at 45 uC followed by RNA purification. RNA purified from splicing reactions was electrophoresed on 8 M urea 8% polyacrylamide gels, then exposed to a phosphorimager screen (Typhoon Trio phosphorimager, GE Healthcare). Alternatively, RNA purified from in vitro splicing reactions was added to RT-PCR reactions as previously described 36 with primers in exons 1 and 2 of MINX (forward: 59-CGGAATTCGAGCTCGCCC-39 and reverse: 59-GGATCCCCACTGGAAAGA-39). PCR products were run on 6% non-denaturing polyacrylamide gels and visualized after staining with ethidium bromide. Spliceosome complex formation assay. In vitro splicing reactions were carried out as described above, placed on ice, and heparin was added to a final concentration of 2 mg ml 21 . Reactions were incubated in the presence of heparin at 30 uC for 5 min and immediately loaded onto 0.75-mm non-denaturing 4% acrylamide-0.4% agarose composite gels. Gels were run at 250 V at room temperature in 13 tris-glycine running buffer for 3 h, then placed on Whatman paper and exposed to a phosphorimager cassette. RNA-seq. pINDUCER11-shBUD31-39UTR-infected MYC-ER HMECs were cultured for 72 h with/without 16 ng ml 21 dox, and for 48 h with/without 300 nM LETTER RESEARCH tamoxifen in triplicates. Total RNA was isolated using the RNeasy kit (Qiagen). RNA samples were rRNA depleted, and NGS libraries were constructed and sequenced as 75 bp paired-end reads by Illumina HiSeq 2000. Quality assessment of RNA-seq. RNA-seq NGS reads quality was evaluated using FastQC application (http://www.bioinformatics.babraham.ac.uk/projects/ fastqc/). Alignment of RNA-seq data. RNA-seq NGS reads were mapped using STAR RNASeq aligner (version 2.3.1). To improve mapping accuracy, the database file of splice junctions (http://it-collab01.cshl.edu/shares/gingeraslab/www-data/ dobin/STAR/STARgenomes/GENCODE/Old/gencode.v14.annotation.gtf.sjdb) was supplied at the genome index generation step with command line option-sjdbOverhang 7, together with http://it-collab01.cshl.edu/shares/gingeraslab/wwwdata/dobin/STAR/STARgenomes/GENCODE/Old/hg19_Gencode14.overhang75/ and default parameters. Duplicate reads were marked with the MarkDuplicates function of the Picard-tools software package (http://picard.sourceforge.net; version 1.107) using default settings. Intron-exon junction definition. To prevent confounding effects in our analysis of IR within HMECs, we confined our analyses to exons in non-overlapping genes that are included within all isoforms of a given gene (75,623 junctions in 6,861 genes).
Intron-exon junctions were obtained using the University of California Santa Cruz Genome Browser 'knownGene' table (downloaded 4 June 2014). Constitutive junctions were defined as junctions that (1) appear in each transcript annotated to a given gene symbol, (2) do not overlap with any transcript annotated to a different gene symbol, and (3) do not mark the start or stop of a transcript. Junction IR calculation. Because analysis of intronic reads may be influenced by the presence of stable RNAs within introns and/or spliced lariats, we calculated junction IR as the ratio of exon-intron reads to exon-exon reads, restricting the analysis to reads directly spanning exon-intron or exon-exon junction sequences. We used R together with the Rsamtools package to calculate IR. In brief, for each intron-exon junction, we extracted all non-duplicate reads overlapping this junction. Next, we assigned these reads into two categories: (1) 'intronic' if the read mapped to at least the first base of the intron, (2) 'exonic' if none of the bases of the read mapped to the first base of the intron and at least one base mapped to a subsequent exon. We counted the total number of reads assigned into each category for each junction. IR was calculated as:
in which IR j,i represents the IR score for junction j in sample i, and I j,i and E j,i refer to the count of reads classified as intronic and exonic for junction j in sample i, respectively. To avoid ratios with 0 in the denominator, we added 1 to each of these counts. The scripts used to conduct this calculation are available on request. We restricted all following analyses to intron-exon junctions with an average of at least 25 total (intronic and exonic) reads in the control and MYC-hyperactivated samples.
Gene IR calculation. For the cumulative distribution analyses, the mean IR score for all junctions in a gene were averaged. Gene annotation. A custom gene annotation file was generated to correspond to the set of intron-exon junctions considered in the IR analysis. In brief, exons were defined as: (1) Permutation-based test of significance. The significance of the difference of empirical cumulative distributions of junction-level IR scores was evaluated using a permutation-based approach. The null hypothesis was that splicing perturbations had no effect on IR changes in the MYC-normal and MYC-hyperactivated states. To model this null hypothesis, the treatment information was blinded to the assignments of MYC activity. We generated a third control sample by randomly selecting half of the junctions from samples 1-control and 2-control. Control and MYC samples were grouped as 6 'normal' samples, and LowBUD31 and Myc_LowBUD31 samples were grouped as 'splicing perturbed' samples. Next, we comprehensively generated all possible normal and splicing perturbed contrasts by subtracting the average of each junction IR score of three normal samples from that of the splicing perturbed group. The empirical distribution of all possible double differences was generated and used to assign significance to the original observations. An analogous approach was used to evaluate the difference of empirical cumulative distributions of gene-level IR scores.
qPCR IR validation assay. Amplification reactions were prepared using SYBR Select Master Mix (Applied Biosystems) according to the manufacturer's instructions with final primer concentration of 300 nM. Reactions were performed using a StepOnePlus Real Time PCR System (Applied Biosystems) with an initial incubation at 95 uC for 10 min followed by 40 cycles of 15 s at 95 uC and 1 min at 60 uC. Primers were designed using Primer3 (available at http://bioinfo.ut.ee/ primer3/) and assessed for quality using Beacon Designer (http://www.premierbiosoft.com/qpcr/) and UNAFold (https://www.idtdna.com/UNAFold). Primers used for each reaction were: C t values from each reaction were interpolated on the standard curve generated using the corresponding control template to approximate the concentration of cDNA template in each experimental sample. These values were then reported as the ratio of intron-exon to total (IE 1 EE) cDNA template in each sample. Transcription pulse assay. MYC-ER HMECs with pINDUCER11-shBUD31-39UTR were cultured with/without 16 ng ml 21 dox and/or with/without 300 nM 4-OHT. Cells were pulsed with 500 mM 4-thiouridine (4-SU, Sigma) for 2 h, and collected for total RNA using RNeasy mini kit (Qiagen). 4-SU-labelled RNA was purified from 20 mg total RNA. Isolation of newly transcribed RNA was performed as described 37 using 100 ml streptavidin beads (Miltenyi Biotec). Poly(A) 1 RNA isolation. Dynabeads Oligo(dT) 25 (Life Technologies) were equilibrated with 50 ml lysis/binding buffer, and total RNA was heat denatured (70 uC for 2 min) before binding poly(A) 1 RNA to Dynabeads. Isolation of mRNA was performed according to manufacturer's instructions. Poly(A) 1 RNA concentrations were measured with a fluorescence plate reader (Molecular Devices) using Quant-iT RiboGreen reagent (Life Technologies). Poly(A) 1 RNA LNA FISH. pINDUCER11-shBUD31-39UTR-transduced MYC-ER HMECs were seeded onto collagen-coated 8-well glass chamber slides and cultured with/without 16 ng ml 21 dox and with/without 300 nM tamoxifen. Cells were treated with/without 2 mg ml 21 actinomycin D (Gibco) or DMSO for 5 h before fixation in 4% formaldehyde and 5% acetic acid in PBS for 15 min at room temperature. Fixed cells were washed with PBS, permeabilized with proteinase K (5 mg ml 21 , Life Technologies) and treated with/without RNase A (100 mg ml 21 , Sigma) for 30 min at 37 uC in PBS. Dehydration of the cells was performed with 70%, 95% and 100% ethanol solutions. FITC-labelled oligo(dT) 25 locked nucleic acid (LNA) probes were heated to 90 uC for 4 min, then cooled to hybridization temperature (55 uC). Dehydrated and dried cells were incubated in 40 nM of LNA probes in hybridization buffer (50% formamide, 2 3 SSC, 50 mM NaPi, pH 7.0, 10% dextran sulphate) overnight at 55 uC. Chamber slides were washed with 5 3 SSC, 1 3 SSC, 0.2 3 SSC and PBS, and dehydrated before counterstaining with DAPI and mounting with Fluoromount-G (Southern Biotech). Cells were imaged using a Nikon Ti-E inverted microscope with 403 air objective and Andor RESEARCH LETTER Zyla 4.2 sCMOS camera. For each treatment condition and actinomycin time point, $150 cells were analysed for mean FITC intensity. Cellular FITC values were adjusted for background fluorescence by subtracting the mean extra-cellular pixel value. Image analysis was performed using Nikon Elements. Luminescent apoptosis assays. Caspase-3/7 activity was assessed in MYC-ER HMECs and breast cancer cell lines by incubating Caspase-Glo 3/7 Reagent with cells in triplicate wells of a 96-well plate and measuring luminescence with a plate reader (Molecular Devices). Luminescence was normalized using cell numbers determined by Hoeschst3321 staining of a duplicate plate, followed by nuclei counting using the Celígo Imaging Cell Cytometer (Brooks). Tumorigenicity and metastasis assays. SUM159 breast cancer cells were transduced with pINDUCER11-shBUD31-39UTR virus and analysed by flow cytometry to confirm .98% transduction. In total 8 3 10 6 transduced cells were injected with matrigel (BD Biosciences) subcutaneously into the flank of four-week-old female athymic nude Foxn1-nu mice (Harlan Labs). Tumour volume was measured using calipers, and once tumours achieved 150 mm 3 , mice were randomized onto and maintained on sucrose water (2dox) or sucrose water with dox (1dox).
For mixed population experiments, MDA-MB-231-LM2 breast cancer cells were individually transduced with pINDUCER11-shRNAs targeting the indicated genes at an MOI appropriate to transduce all cells (1.3-1.5). The individual populations were mixed at equal ratios in vitro and expanded before injection. Around 3 3 10 6 or 2 3 10 5 mixed population cells were injected subcutaneously into the right flank or into the lateral tail vein of four-week-old female athymic nude Foxn1-nu mice (Harlan Labs), respectively. Subcutaneous tumour volume was measured with calipers over time. Mice were randomized onto sucrose water (2dox) or sucrose water with dox (1dox) after tumours exceeded 150 mm 3 . Lung metastatic progression was monitored and quantified using noninvasive bioluminescence as described previously 19 . When tumours reached 1,000 mm 3 or the total luminescence flux reached 1 3 10 9 , genomic DNA from dissected tumours or lungs were collected using the QIAamp DNA mini kit (Qiagen). qPCR was performed with SYBR Green PCR Master Mix (Life Technologies) using manufacturer's recommendations and the following primers. Experimental target C t values were normalized to the TRE C t values, and NCOR2 was used as a negative control.
The following primers were used. For SD6 drug infusion studies, 3 3 10 6 or 2 3 10 5 MDA-MB-231-LM2 breast cancer cells were injected into the flank or lateral tail vein of four-week-old female athymic nude Foxn1-nu mice (Harlan Labs), respectively. For mice with subcutaneous tumours, jugular vein catheters (SAI Infusion Technologies) were surgically implanted into each mouse 13-16 days after injection, and were randomized to receive vehicle (n 5 11) or SD6 (n 5 10) infusion. Tail-vein-injected mice were randomized to receive vehicle (n 5 7) or SD6 (n 5 6) infusion 1 day after tail vein injections. Animals received daily infusions of vehicle (10% 2-hydroxypropyl-bcyclodextrin dissolved in 50 mM Na 2 HPO 4 /NaH 2 PO 4 , pH 7.4) or 50 mg kg 21 of SD6 for 20 consecutive days (subcutaneous cohort) or 10 consecutive weekdays (tail vein cohort). Mice were infused via jugular catheter at a rate of 3.5 ml min 21 with a Fusion 200 Touch Syringe Pump (SAI Infusion Technologies). The total volume infused did not exceed 500 ml per day. Subcutaneous tumour volumes were monitored with calipers, and lung metastatic progression was monitored with noninvasive bioluminescence. Mice were euthanized once tumours reached 2,000 mm 3 or the total luminescence flux reached 1 3 10 9 . In progression-free survival analyses, progression is defined as fivefold increase in pulmonary bioluminescence relative to initial values or fourfold increase in subcutaneous tumour volume relative to its volume at time of randomization.
Investigators responsible for monitoring and measuring the xenografts of individual tumours were not blinded. Simple randomization was used to allocate animals to experimental groups. All animal studies were performed in accordance with institutional and national animal regulations. Animal protocols were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine.
Power analysis was used to determine appropriate sample size to detect significant changes in animal survival, which were based on previous survival analyses in our laboratory. All animals were included in analyses. Pooled shRNA screens in breast cancer cell lines. Pooled shRNA screens were performed on 68 breast cancer lines and four non-malignant immortalized mammary epithelial lines, essentially as described 38 . In brief, cells are infected with a lentiviral shRNA library at a MOI of 0.3, and passaged under standard conditions. At 4 and 8 doublings, respectively, DNA is isolated and hybridized to a customized chip to assess shRNA dropout. A detailed description of the results of these screens will be published separately (R.M., A. S. and B.G.N., manuscript in preparation). Correlation between MYC dependency and spliceosome dependency. First, to calculate MYC dependency scores using probable on-target hairpins, we used assay observations associated with 3 hairpins incorporated into the first ATARIS 39 solution for MYC. MYC dependency scores were generated using a hierarchical linear model, with pooled shRNA screen observations as the independent variable and two regression covariates: initial signal intensity (with coefficient b 0 ) and linear time-course dropout trend (with coefficient b 1 ). The dropout trend is calculated for each cell line separately, resulting in a per-cell-line MYC dropout score (the value of coefficient b 1 ).
Second, the MYC dependency score was used in a hierarchical linear model to search for associations with the essentiality of other genes (such as spliceosome encoding genes). This model uses pooled shRNA screen observations as the independent variable and three regression covariates: initial assay signal intensity (with coefficient b 1 ), linear time-course dropout trend (with coefficient b 1 ), and an interaction term between dropout trend and MYC dependency score (with coefficient b M ). The P-value associated with the interaction term b M is used to determine whether a significant association exists. A detailed description of this approach will be published elsewhere (A.S., R.M. and B.G.N., manuscript in preparation).
A summary statistic using results from the single-gene analyses was used to test the significance of the association between MYC dependency and the essentiality of a gene set. For a gene set containing genes g, we calculate the gene set summary statistic as { X gene g sign(b M )log 10 (P value(b M )) in which sign(b M ) and Pvalue(b M ) indicate the values associated with the regression coefficient b M . The resulting metric, termed a siMEM (mixed-effect model) score, indicates the significance and correlation between sensitivity to MYC shRNAs and sensitivity to a group of shRNAs targeting a gene set (such as those targeting the spliceosome). A gene set (for example, spliceosome genes) for which a substantial number of genes are significantly associated with MYC dependency, and all with the same direction (sign) of association, will have a large positive score.
When calculated for the gene set consisting of the core spliceosome, this value summarizes the direction and strength of the significance observed across genes in the spliceosome. To determine whether this observation is significant, the same statistic is calculated for 100,000 randomly drawn gene sets of the same size as the core spliceosome, yielding the null distributions of gene set summary statistics in Fig. 4b, c . Statistical analysis. All experiments were performed on biological replicates unless otherwise specified. Sample size for each experimental group/condition is reported in the appropriate figure legends and methods. For cell culture experiments, sample size was not predetermined, and all samples were included in analyses. For significance testing, analyses were chosen if data met the assumptions of the tests. Data was checked for comparable variance before statistical analysis. Statistically significant differences between control and experimental groups were determined using two-tailed unpaired Student's t-test, one-way ANOVA with Tukey-Kramer minimum significant difference test, Mann-Whitney test, Kolmogorov-Smirnov test, Wilcoxon test, permutation-based test of significance, and log-rank test as indicated in the appropriate figure legend and methods text. Figure 7 | MYC-dependent breast cancer cells require BUD31 for in vitro and in vivo growth. a, Relative cell number of SUM159 cells with doxycycline-inducible shBUD31 in vitro (mean 6 s.e.m., n 5 8 technical replicates, ***P , 0.001, two-tailed Student's t-test). b, Caspase-3/7 luminescence in BUD31-depleted SUM159 cells (mean 6 s.e.m., n 5 3 technical replicates, ***P , 0.001, two-tailed Student's t-test). c, d, SUM159 cells engineered with dox-inducible shBUD31 were subcutaneously transplanted into mice and randomized onto dox treatment (2dox n 5 10, 1dox n 5 9). Loss of BUD31 in SUM159 xenografts inhibits tumour growth (mean 6 s.e.m., ***P , 0.001 at day 21, two-tailed Student's t-test) (c) and prolongs progression-free survival (d) in nude mice (P-value, log-rank test). 
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G2015 Macmillan Publishers Limited. All rights reserved Extended Data Figure 9 | Schematic for in vivo barcode-based competition assay. LM2 cells transduced with inducible shRNAs targeting negative control genes or candidate genes were mixed at an equal ratio. This mixed population was transplanted into mice, and tumours were allowed to form in the presence or absence of dox. At the experimental endpoint, genomic DNA was isolated for comparisons of relative barcode (shRNA) abundance in tumour genomic DNA.
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G2015 Macmillan Publishers Limited. All rights reserved Extended Data Figure 10 | Spliceosome inhibitor SD6 inhibits MYCdependent cancer cells in vitro and in vivo. a, MYC-dependent breast cancer cells (SUM159 and LM2) and MYC-normal immortalized epithelial cells (F7 and HME1) were cultured with SD6 at low density and analysed for clonogenic growth. b, MYC-repressible human B-cell line P493-6 was treated with or without 100 nM SD6 in the absence or presence of MYC hyperactivation for four days, and cells were counted for relative cell number changes (mean 6 s.e.m., n 5 3 biological replicates, ***P , 0.001, one-way ANOVA). c, Kaplan-Meier survival analysis of nude mice with pulmonary seeding of LM2 cells treated with or without SD6 for 10 days (vehicle n 5 7, SD6 n 5 6, P-value by log-rank test).
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